Buyers sourcing vector development and manufacturing services should read the estimated 25% share less as a snapshot of popularity and more as a reflection of where the installed base of clinical and commercial programs currently sits. Ex vivo modification of T cells and other immune cells for CAR-T and related therapies depends on a vector that can integrate a transgene stably into a dividing cell population, and lentiviral platforms remain the workhorse for that step. That dependency shapes procurement: capacity at contract development and manufacturing organizations for lentiviral production is booked well in advance, and lead times for vector lots feed directly into clinical trial timelines and, increasingly, into commercial supply agreements.
What is driving the share
The pull toward lentiviral platforms comes from the expanding pipeline of ex vivo cell therapies, most visibly in oncology, where transient transfection-based production and suspension-adapted producer cell lines have made scale-out more tractable than it was a few years ago. Outsourcing to specialist CDMOs has grown alongside this, as biotech sponsors without in-house viral manufacturing capacity look to secure slots on production suites built specifically for lentiviral processes.
What would change it
A shift toward in vivo gene therapies built on AAV, or the maturation of non-viral delivery methods such as lipid nanoparticle-based or transposon-based engineering for ex vivo work, would erode this position over time. Improvements in producer cell line titers could also change the economics of lentiviral production without changing the underlying share directly. The Viral Vector Development Service Market report sets the 2025 market at an estimated USD 1,311.2 million, reaching USD 4,483.35 million by 2032 — a 19.2% CAGR — and covers the full product mix this figure sits within.
What this figure does not tell you
This is a point-in-time share, not a trend line, and it does not indicate whether the 25% figure is rising or falling. It does not break out which applications or regions contribute most to that share, and it says nothing about pricing, margins, or capacity utilization at individual manufacturing sites.